Murine Ulcerative Dermatitis in C57BL/6 Mice: Clinical Workup

Bottom line

Murine ulcerative dermatitis (UD) is a pruritic, self-traumatizing syndrome recognized particularly in C57BL/6 (B6) mice and genetically engineered lines on a B6 background. Diagnose the syndrome only after evaluating ectoparasites, wounds, infection, neoplasia, husbandry, and genotype-associated disease; lesion location alone is insufficient. The evidence for risk factors is heterogeneous and comparative treatment evidence is weak, so management should combine cause-directed investigation, welfare protection, objective follow-up, and predefined humane endpoints.[1]

Case definition and phenotype

The classic laboratory phenotype is intense scratching with ulcerative skin lesions over the dorsal cervicothoracic region.[1] Early findings may be excoriation, alopecia, or small crusts; repeated trauma can produce coalescing crust, erosion, and full-thickness epidermal ulceration.[2] Secondary inflammation and microbial colonization can obscure the initiating process.

Start with a reproducible description rather than the shorthand “UD.” Record strain and substrain, genetic modification, sex, age, diet, study manipulation, cage density, cagemates, lesion onset, prior cases in the room or line, treatments, and pruritic behavior. Map every lesion and distinguish intact crust from erosion and ulceration. Note discharge, odor, swelling, peripheral lymph nodes, body condition, hydration, mobility, and whether the mouse can eat, drink, nest, and avoid further trauma.

The label should be used cautiously outside its evidence base. A systematic review focused on spontaneous UD in wild-type C57BL/6 mice and, under relaxed criteria, genetically engineered mice on a B6 background.[1] Findings from these populations do not establish prevalence, age risk, sex risk, or treatment efficacy in pet mice of unknown ancestry or in unrelated laboratory strains.

Differential diagnosis and workup

Rule out transmissible and remediable causes before treating the lesion as idiopathic UD. Differentials include fur mites and other ectoparasites, barbering, bite wounds, bacterial or fungal dermatitis, abscessation, contact or irritant injury, thermal injury, neoplasia with surface ulceration, and a genotype-associated dermatopathy. Distribution helps organize the list but does not replace diagnostics. Fight wounds may involve accessible targets and cage dynamics; mite-associated pruritus can create a similar self-trauma loop.

Review sentinel or colony health information, incoming-animal history, recent transfers, cage-change patterns, bedding, sanitation products, feed lots, environmental temperature and humidity, and study compounds. Examine cagemates and comparable animals in the same genetic line. A cluster across cages suggests a different investigative pathway from one lesion in an aged individual. Coordinate with the attending veterinarian, facility management, investigators, and diagnostic laboratory so that animal care and study-integrity questions are addressed together.

Select tests from the differential. Tape preparation, superficial and deep skin scraping, fur pluck, cytology, and parasite PCR may be useful depending on the suspected agent and colony program. Culture is most informative when collected from a clinically meaningful depth and interpreted with cytology; a surface isolate does not prove primary infection. Biopsy should include lesion edge and appropriate unaffected comparison skin when the result will change management. Histopathology can confirm ulceration and characterize inflammation, but chronic scratching may erase features of the initiating disease.

Document whether diagnostic animals received topical or systemic treatment before sampling. If a genetically modified line has a plausible skin phenotype, review background-strain controls and line-specific pathology rather than automatically attributing all lesions to ordinary B6 UD.

What the systematic review establishes

The 2015 systematic review searched three databases and screened 347 articles. Eleven publications on risk factors met the original inclusion criteria, while no treatment publication met all original criteria. When the authors relaxed eligibility to include both wild-type B6 mice and genetically engineered mice on a B6 background, they reviewed 12 risk-factor publications and 3 treatment publications.[1] Only 1 of those 3 treatment publications included an untreated group or alternative-therapy control.[1]

Those numbers describe a literature search, not animals enrolled in one experiment. They support a guarded reading of common recommendations. The review found that dietary factors, particularly caloric restriction, appeared to influence risk; female sex was inconsistently associated with greater risk; and UD most often occurred at 13–24 months in the reviewed studies.[1] “Most often” is not an onset cutoff, and inconsistent sex results should not be converted into a universal female predisposition.

The review also emphasizes that pathogenesis remains poorly understood.[1] Proposed mechanisms and associations should therefore be separated from demonstrated patient-level causes. A mouse may fit the phenotype without revealing why it developed, and a colony-level association does not prove the driver in an individual cage.

Objective severity tracking

Use the same observer, lighting, body map, and measurement method whenever possible. Photograph lesions with a scale, record length and affected region, and quantify scratching over a defined observation period. Avoid a vague “better/worse” assessment that combines lesion contraction, crusting, and reduced activity without distinguishing them. A mouse that scratches less because it is systemically ill is not improving.

A prospective C57BL/6Crl study followed 200 mice and developed a severity score based on scratching bouts, lesion character, and lesion size, including lesion length and affected regions.[2] Lesion character was ordered from excoriations and small punctate crusts through coalescing crust, erosion, and ulceration.[2] This offers a model for longitudinal documentation, but it is not a universally validated diagnostic instrument for every strain, study, or clinical setting.

In that cohort, 43 of 200 mice developed clinical UD; 37 of those 43 were in the group followed to 19 months.[2] At the 13-month time point, clinical UD occurred in 3 of 50 males and 3 of 50 females, both 6%. In the 19-month cohort, it occurred in 16 of 60 males (26.7%) and 21 of 60 females (35%).[2] These are cohort-specific incidences in C57BL/6Crl mice under the reported conditions, not prevalence estimates for all B6, genetically engineered, laboratory, or pet mice.

Treatment planning under weak evidence

First treat a demonstrated cause: eradicate confirmed ectoparasites at the appropriate colony scope, address aggression and enclosure conflict, remove an irritant, manage infection supported by cytology or culture, or pursue a mass diagnosis. When no primary cause is established, the treatment plan should target pruritus, inflammation, microbial complications, barrier damage, and self-trauma while preserving hydration, nutrition, thermoregulation, and normal behavior.

Do not present a favored colony protocol as proven therapy. The systematic review found no treatment publication that met all original quality criteria and only limited controlled comparisons after criteria were relaxed.[1] Differences in formulation, route, lesion severity, genetic background, endpoints, spontaneous fluctuation, and euthanasia criteria make casual cross-study comparisons unreliable.

Choose interventions with the attending veterinarian and document drug, formulation, concentration, route, frequency, duration, and concurrent measures in the medical and study record. Consider whether topical handling, ingestion by cagemates, grooming, occlusion, or a device introduces additional stress or study interference. Avoid extrapolating an anecdotal response into a colony standard without a defined case definition and outcome measure.

A short reassessment interval is appropriate when self-trauma is active. At each check, record scratching, lesion dimensions and character, discharge, body weight, hydration, behavior, and adverse effects. Define failure before treatment begins: continued lesion expansion, deeper ulceration, uncontrolled pruritus or pain, systemic decline, inability to eat or drink, or interference with essential function should trigger escalation or a humane endpoint rather than serial unstructured remedies.

Colony and study considerations

Separate clinical care decisions from prevalence claims and experimental inference. Create a line list containing animal ID, line, sex, birth date, cage, room, onset, distribution, score, diagnostics, treatment, and outcome. Look for clustering by pedigree, cage, rack, room, feed or bedding lot, procedure, and investigator. Preserve samples when an outbreak pattern or novel phenotype is suspected.

Housing changes require judgment. Remove an aggressor or protect an injured mouse when active trauma is documented, but recognize that single housing can alter welfare and study variables. Any separation, enrichment change, diet change, or environmental intervention should be clinically justified and captured as a protocol-relevant event.

Communicate uncertainty clearly. The review literature can justify enhanced surveillance of aging B6-background colonies, but it cannot supply a universal prediction for a particular mouse.[1] Likewise, the prospective C57BL/6Crl cohort informs progression and scoring but does not validate the same incidence under different genetics, diets, housing, or endpoints.[2]

Frequently Asked Questions

Is ulcerative dermatitis unique to C57BL/6 mice?

No. The syndrome is especially recognized in B6 and B6-background research mice, but ulcerative skin disease has multiple causes and can occur in other mice. Confirm the phenotype and investigate differentials rather than diagnosing from strain alone.

Does a dorsal neck ulcer establish the diagnosis?

No. Dorsal cervicothoracic lesions fit the classic phenotype, but mites, self-trauma, infection, wounds, irritants, and masses can overlap. History, colony context, examination, and targeted testing are required.

Are female B6 mice at higher risk?

Not consistently across studies. The Sargent systematic review found that female sex was associated with higher risk in some publications but not others. Sex should therefore be recorded and analyzed, not treated as a universal causal rule.

At what age does murine UD occur?

The systematic review found that UD occurred most often at 13–24 months in the studies reviewed. That is a summary of selected B6 and B6-background laboratory literature, not an exclusion rule for younger mice or a forecast for every colony.

Is there a proven best treatment?

No. The systematic review found that no treatment publication met all original quality criteria; after criteria were relaxed, only 3 treatment publications were reviewed and only 1 included an untreated or alternative-therapy control. Treat demonstrated causes and measure individual response objectively.

Can the C57BL/6Crl severity score be used as a diagnostic test?

No. The study's score combined scratching bouts, lesion character, and lesion size to follow severity. It is a useful documentation model, but it does not distinguish UD from every differential and was not validated across all mouse populations.

When should a humane endpoint be considered?

Use protocol-approved endpoints and veterinary judgment. Progressive or deep ulceration, uncontrolled pain or pruritus, systemic decline, inability to eat or drink, or failure of a time-limited treatment plan should prompt escalation and consideration of euthanasia.